Literature DB >> 7856672

Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis.

M J Paidas1, R L Berkowitz, L Lynch, C J Lockwood, R Lapinski, J G McFarland, J B Bussel.   

Abstract

OBJECTIVE: This report describes the increased risks of cordocentesis in fetuses affected with alloimmune thrombocytopenia. STUDY
DESIGN: As part of a multicenter treatment study clinical and laboratory data from five pregnancies with alloimmune thrombocytopenia in which there was a fetal or neonatal loss associated with cordocentesis were reviewed. The fetal or neonatal deaths were all thought to be a result of exsanguination. These fetuses were compared with a group of 44 affected fetuses who underwent the same procedure but who survived. The data were analyzed by the Wilcoxon rank-sum test and the two-tailed Fisher's exact test. A p value < 0.05 was considered significant.
RESULTS: The mean platelet count at cordocentesis was significantly lower in the cases than in the controls (5.8 vs 32.8 x 10(9)/L, p = 0.005). The incidence of antenatal intracranial hemorrhage in the untreated sibling of the prior affected pregnancy was significantly greater in the cases than in the controls (two of five vs one of 42, p = 0.02).
CONCLUSION: Fetuses affected with alloimmune thrombocytopenia are at increased risk for fatal exsanguination associated with cordocentesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7856672     DOI: 10.1016/0002-9378(95)90559-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective.

Authors:  Cheryl A Vinograd; James B Bussel
Journal:  Haematologica       Date:  2010-11       Impact factor: 9.941

2.  Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases.

Authors:  A Davoren; P McParland; C A Barnes; W G Murphy
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

3.  Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort.

Authors:  Marije M Kamphuis; Heidi Tiller; E S van den Akker; Magnus Westgren; Eleonor Tiblad; Dick Oepkes
Journal:  Fetal Diagn Ther       Date:  2016-10-12       Impact factor: 2.587

Review 4.  Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management.

Authors:  Julie A Peterson; Janice G McFarland; Brian R Curtis; Richard H Aster
Journal:  Br J Haematol       Date:  2013-02-06       Impact factor: 6.998

5.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

6.  Serial intrauterine transfusions for a hydropic fetus with severe anemia and thrombocytopenia caused by parvovirus: lessons learned.

Authors:  Pedro S Argoti; Michael Bebbington; Michael Adler; Anthony Johnson; Kenneth J Moise
Journal:  AJP Rep       Date:  2013-03-19

Review 7.  Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

Authors:  Heidi Tiller; Anne Husebekk; Maria Therese Ahlen; Tor B Stuge; Bjørn Skogen
Journal:  Int J Womens Health       Date:  2017-04-19

8.  Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia.

Authors:  Brian Vadasz; Pingguo Chen; Issaka Yougbaré; Darko Zdravic; June Li; Conglei Li; Naadiya Carrim; Heyu Ni
Journal:  Genes Dis       Date:  2015-06-01

9.  Identification and follow-up of pregnant women with platelet-type human platelet antigen (HPA)-1bb alloimmunized with fetal HPA-1a.

Authors:  Marzena Dębska; Małgorzata Uhrynowska; Katarzyna Guz; Izabella Kopeć; Elżbieta Lachert; Agnieszka Orzińska; Piotr Kretowicz; Jolanta Antoniewicz-Papis; Romuald Dębski; Magdalena Łętowska; Anne Husebekk; Ewa Brojer
Journal:  Arch Med Sci       Date:  2016-11-15       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.